Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK4290 in refractory wet age-related macular degeneration
2017-004228-31Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BI 144807 in exudative macular degeneration, sponsored by Alkahest, Inc. Primary endpoint: Change in BCVA (ETDRS). Started Dec 2017; status: completed.
02
Drugs
BI 144807
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2017-004228-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004228-31.